ProQR Therapeutics (NASDAQ:PRQR) Coverage Initiated at Evercore ISI

Stock analysts at Evercore ISI initiated coverage on shares of ProQR Therapeutics (NASDAQ:PRQR) in a report released on Tuesday, Marketbeat reports. The firm set an “outperform” rating and a $5.00 price target on the biopharmaceutical company’s stock. Evercore ISI’s price objective suggests a potential upside of 201.20% from the company’s current price.

Other research analysts have also recently issued reports about the company. Oppenheimer started coverage on ProQR Therapeutics in a report on Friday, January 10th. They issued an “outperform” rating and a $15.00 price objective on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research note on Friday, March 14th. Citigroup raised ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research report on Monday, March 10th. Finally, HC Wainwright upped their target price on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, March 14th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.75.

ProQR Therapeutics Price Performance

Shares of PRQR stock opened at $1.66 on Tuesday. The company has a market capitalization of $174.65 million, a PE ratio of -5.19 and a beta of 0.25. The firm’s 50-day moving average is $1.58 and its two-hundred day moving average is $2.49. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $4.62.

Institutional Trading of ProQR Therapeutics

Several hedge funds have recently made changes to their positions in the business. Jane Street Group LLC acquired a new stake in ProQR Therapeutics during the 4th quarter worth approximately $30,000. Invesco Ltd. acquired a new stake in ProQR Therapeutics in the 4th quarter valued at about $32,000. Alpine Global Management LLC acquired a new position in shares of ProQR Therapeutics during the fourth quarter worth about $39,000. Two Sigma Securities LLC acquired a new position in shares of ProQR Therapeutics during the fourth quarter worth about $40,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of ProQR Therapeutics during the fourth quarter worth approximately $54,000. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).